Comgest Global Investors S.A.S. Biogen Inc. Transaction History

Comgest Global Investors S.A.S.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$217.44 - $243.88 $2.74 Million - $3.07 Million	-12,600 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$219.29 - $241.72 $43,858 - $48,344	200 Added 1.61%	12,600 $2.95 Million
Q1 2019 May 09, 2019	SELL	$216.71 - $338.96 $975,195 - $1.53 Million	-4,500 Reduced 26.63%	12,400 $2.93 Million
Q3 2018 Nov 06, 2018	SELL	$293.51 - $383.83 $616,371 - $806,043	-2,100 Reduced 11.05%	16,900 $5.97 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $260,130 - $367,910	1,000 Added 5.56%	19,000 $5.2 Million
Q4 2017 Feb 09, 2018	BUY	$307.64 - $344.58 $307,640 - $344,580	1,000 Added 5.88%	18,000 $5.73 Million
Q3 2017 Nov 07, 2017	BUY	$281.15 - $329.69 $224,919 - $263,752	800 Added 4.94%	17,000 $5.32 Million
Q2 2017 Aug 09, 2017	BUY	N/A	16,200	16,200 $4.4 Million

1,024

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Comgest Global Investors S.A.S., based on Form 13F filings with the SEC.

Stay updated on Comgest Global Investors S.A.S. with notifications on news.